Abstract:Adoptive cell immunotherapy (ACT) is a vibrant field of cancer treatment that began progressive development in the 1980s. One of the most prominent and promising examples is chimeric antigen receptor (CAR) T-cell immunotherapy for the treatment of B-cell hematologic malignancies. Despite success in the treatment of B-cell lymphomas and leukemia, CAR T-cell therapy remains mostly ineffective for solid tumors. This is due to several reasons, such as the heterogeneity of the cellular composition in solid tumors, the need for directed migration and penetration of CAR T-cells against the pressure gradient in the tumor stroma, and the immunosuppressive microenvironment. To substantially improve the clinical efficacy of ACT against solid tumors, researchers might need to look closer into recent developments in the other branches of adoptive immunotherapy, both traditional and innovative. In this review, we describe the variety of adoptive cell therapies beyond CAR T-cell technology, i.e., exploitation of alternative cell sources with a high therapeutic potential against solid tumors (e.g., CAR M-cells) or aiming to be universal allogeneic (e.g., CAR NK-cells, γδ T-cells), tumor-infiltrating lymphocytes (TILs), and transgenic T-cell receptor (TCR) T-cell immunotherapies. In addition, we discuss the strategies for selection and validation of neoantigens to achieve efficiency and safety. We provide an overview of non-conventional TCRs and CARs, and address the problem of mispairing between the cognate and transgenic TCRs. Finally, we summarize existing and emerging approaches for manufacturing of the therapeutic cell products in traditional, semi-automated and fully automated Point-of-Care (PoC) systems.

Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

Challenges and new technologies in adoptive cell therapy

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects

CAR T cells: Building on the CD19 paradigm

Prospects and challenges for use of CAR T cell therapies in solid tumors

CAR-T cell therapy: current limitations and potential strategies

Current Clinical Application of the CAR-T Cell Therapy

CAR T cell immunotherapy for human cancer

CAR T-Cell Therapy: Progress and Prospects

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

Emerging Strategies in TCR-Engineered T Cells

Evolving CAR-T-Cell Therapy for Cancer Treatment: From Scientific Discovery to Cures

Adoptive Immunotherapy beyond CAR T-Cells

Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments